The genes are mostly already on the map. The work now is interpretation.
In one of the largest genetic studies of its kind, researchers examining nearly 30,000 families have arrived at a quietly revolutionary conclusion: the genes responsible for most recessive developmental disorders in children are already known to science. Published in Nature Genetics in September 2024, the work by the Wellcome Sanger Institute and GeneDx suggests that the frontier of diagnosis lies not in discovery, but in interpretation — in learning to read more carefully what has already been written. For countless families whose children carry unexplained conditions, the answers may already exist within data already collected, awaiting only a more practiced eye.
- Tens of thousands of families with children affected by developmental disorders have long waited for diagnoses that standard genetic testing failed to deliver — a silence this study now begins to break.
- The assumption driving much of genetic research — that new gene discoveries are the key to unlocking undiagnosed cases — is directly challenged by the finding that known genes account for 84% of recessive disorder cases.
- A critical blind spot emerges: roughly one in eight patients may carry multiple interacting genetic factors, a complexity that conventional diagnostic pipelines routinely overlook.
- Reanalyzing existing genetic data with updated methods could double diagnosis rates without collecting a single new sample — a potentially transformative shortcut hiding in plain sight.
- Non-European populations remain underserved, with diagnostic gaps tracking closely to how underrepresented those ancestries are in prior research, making diversity in future studies both a scientific and ethical imperative.
A team of geneticists has completed the largest and most ethnically diverse study yet into recessive genetic mutations that cause developmental disorders in children. Drawing on data from nearly 30,000 families — six times the scale of previous work — researchers from the Wellcome Sanger Institute and GeneDx examined conditions ranging from Joubert syndrome to Tay-Sachs disease. Crucially, more than 20 percent of participants came from non-European ancestries, a meaningful departure from a field historically skewed toward European populations.
The headline finding, published in Nature Genetics in September 2024, reframes where the real diagnostic opportunity lies. Known genes — already catalogued in medical literature — account for approximately 84 percent of cases caused by recessive genetic variants, a substantial jump from earlier estimates. Three previously unlinked genes were also identified: KBTBD2, CRELD1, and ZDHHC16. But these discoveries are the exception. The map of disease genes, the study suggests, is largely already drawn.
What remains is the harder work of reading it correctly. The team found that around 12.5 percent of patients may carry multiple genetic factors shaping their condition — a layer of complexity that standard diagnostic approaches routinely miss. More immediately, reanalyzing existing genetic data with updated methods could potentially double the number of patients who receive a diagnosis, without requiring new samples. Families already in the system could find answers simply by revisiting what was collected years ago.
Senior author Dr. Hilary Martin noted that patients with one confirmed diagnosis might harbor additional rare genetic changes that alter severity or open new treatment pathways. The practical implication is a shift in priorities: rather than chasing new gene discoveries, the field should invest in better interpretive tools — especially for populations long underrepresented in genetic research. For many families, the answers may already exist in their data, waiting for the right lens to bring them into focus.
A team of geneticists has completed the largest and most ethnically diverse study yet into how recessive genetic mutations cause developmental disorders in children. The work, which analyzed genetic data from nearly 30,000 families, upends the conventional wisdom about where future diagnostic breakthroughs will come from—and suggests that the real opportunity lies not in discovering new disease genes, but in learning to read the ones we already know.
Researchers from the Wellcome Sanger Institute and GeneDx combined data from two major cohorts to examine families affected by conditions like Joubert syndrome, Bardet-Biedl syndrome, and Tay-Sachs disease. What made this study distinctive was its scope: it included six times more families than previous work, and crucially, over 20 percent of participants came from non-European ancestries. This diversity matters because genetic disease patterns vary significantly across populations, and most prior research has been skewed toward European ancestry groups.
The headline finding, published in Nature Genetics in September 2024, is striking in its simplicity. Known genes—ones already catalogued in medical literature—account for approximately 84 percent of cases caused by recessive genetic variants. This represents a substantial jump from earlier estimates. The implication is clear: the era of hunting for entirely new disease genes has been largely successful. The genes are mostly already on the map. What remains is the harder, less glamorous work of interpretation.
The variation across ancestry groups tells its own story. The proportion of patients affected by recessive variants ranged from as low as two percent to as high as 19 percent depending on ancestral background. This disparity tracks closely with consanguinity—the prevalence of marriages between relatives—which is more common in some populations than others. The researchers also identified three genes newly linked to developmental disorders: KBTBD2, CRELD1, and ZDHHC16. These discoveries will help some previously undiagnosed families find answers. But they are the exception, not the rule.
Perhaps the most consequential finding concerns what lies hidden in plain sight. The team estimates that roughly 12.5 percent of patients may carry multiple genetic factors contributing to their condition—a layer of complexity that standard diagnostic approaches often miss. More immediately practical: reanalyzing existing genetic data using updated methods and knowledge could potentially double the number of patients who receive a diagnosis, without requiring new blood samples or additional testing. Families already in the system could get answers simply by looking at what was collected years ago through fresh eyes.
Dr. Kartik Chundru, the study's lead author, emphasized that these findings create a roadmap for clinicians. Reanalysis of genetic data with improved interpretation methods can yield new diagnoses without additional samples. Dr. Hilary Martin, a senior author at the Wellcome Sanger Institute, highlighted another dimension: patients with one confirmed genetic diagnosis might actually harbor additional rare genetic changes that modify their condition, alter its severity, or open new treatment possibilities. The complexity of genetic disease, in other words, is greater than we typically assume.
The practical implication is a shift in research priorities. Rather than continuing to pour resources into gene discovery, the field should invest in better tools for interpreting variants in known genes—particularly in populations that have been historically underrepresented in genetic research. For families with children whose developmental disorders remain unexplained despite genetic testing, this work suggests that answers may already exist in their data, waiting for the right analytical lens to bring them into focus.
Citações Notáveis
Reanalyzing genetic data with updated methods and knowledge can lead to new diagnoses for patients without needing additional samples— Dr. Kartik Chundru, lead author
Many patients with one known genetic diagnosis might actually have additional rare genetic changes contributing to their condition, which could improve understanding and offer new treatment options— Dr. Hilary Martin, Wellcome Sanger Institute
A Conversa do Hearth Outra perspectiva sobre a história
So if we already know most of the genes that cause these disorders, why are so many cases still undiagnosed?
Because knowing a gene exists and knowing what to do with it are two different things. A variant in a known gene might be so rare, or so unusual in its form, that nobody's written about it yet. The data is there. The interpretation is missing.
And the study found that reanalyzing old data could double diagnoses?
Yes. Families gave samples years ago. Technology and knowledge have advanced since then. If you run those same samples through current analysis methods, you find things you couldn't see before. No new test needed.
Why does ancestry matter so much here?
Because genetic disease patterns aren't universal. A variant that's common in one population might be rare in another. And consanguinity—family marriages—changes the odds of recessive conditions appearing. If you only study European ancestry groups, you miss half the picture.
What about those three newly discovered genes?
They're real and they matter for the families they help. But they're not the main story. The main story is that we've already found most of the genes. The work now is interpretation, not discovery.
What does it mean that 12.5 percent of patients might have multiple genetic causes?
It means a child's condition might not have one simple explanation. Multiple rare variants could be working together. That changes how you treat it, how you counsel the family, what to expect.
So what changes in practice?
Clinicians need to look harder at known genes first, not assume they need to find something new. And research needs to include more diverse populations, because the patterns we see in European ancestry groups don't hold everywhere.